Untitled

Abstract

The present research work was planned to formulate poloxamer 407 based hydrogel formulations of metronidazole and the evaluation of various parameters like swelling behavior, drug PH stability, in-vitro and in-vivo drug release, and in-vitro cytotoxic activity. Two different concentrations of metronidazole hydrogel formulations were prepared using poloxamer 407 and were assessed by a validated HPLC method for drug content, pH stability, and in-vivo drug release. Further, in-vitro anticancer activity was evaluated using sulphorhodamine B (SRB) assay in SCC29 cell lines. Both the formulations F1 and f2 showed better pH stability at pH 3.5, 5.5 and 6.8. The formulation F1 was able to absorb about 152% of its weight of water within 80 min, whereas F2 absorbed 167.4% of its weight of water and remains constant over 100 min. In-vitro and in-vivo drug release pattern showed half-life at 6 h, AUC 0−t 692 and 684ng h/ml, C max 1059 and 1142 ng/ml for F1 and F2 respectively. Hydrogel formulation F1 showed improved percentage control growth when compared to F2 hydrogel formulation and metronidazole alone.

DataSheet1.PDF

“…Moreover, because of the porous structure of both hydrogels and scaffolds, there was a broad hydrogel-liquid interface (Colucci et al, 2021). Through the diffusion of drugs on the surface, the broad interface was initially mainly responsible for rapid release, which was acceptable in the clinic and consistent with drug delivery patterns in other studies (Katakam et al, 2019;Tundisi et al, 2021). Later, the degradation rate was influenced by the drug diffusion and hydrogel degradation and the interlink of chemical bonds and intermolecular hydrogen bonds between drugs and the poloxamer 407 (Borges et al, 2021).…”